Clinical effects of colesevelam in hispanic subjects with primary hyperlipidemia and prediabetes

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 14-20

  Rosenstock, Julio ^a   Hernandez Triana, Eric ^b   Handelsman, Yehuda ^c   Misir, Soamnauth ^d   Jones, Michael R ^d  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c Metabolic Institute of America   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

Colesevelam; Hispanic; Hyperlipidemia; Prediabetes

Indexed keywords

APOLIPOPROTEIN B; COLESEVELAM; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ALLYLAMINE; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIMARY HYPERLIPIDEMIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT PLANNING; UPPER ABDOMINAL PAIN; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ETHNOLOGY; TREATMENT OUTCOME;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, HDL; MALE; PREDIABETIC STATE; TREATMENT OUTCOME;

EID: 84871699451     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2564     Document Type: Article

References (24)

1. International Diabetes Federation. IDF Diabetes Atlas; Central and South America. 2009. http://www.idf.org/diabetesatlas/south-and-central-america. Accessed August 18, 2011.
2. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32(2):287-294.
3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-1890.
4. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
5. Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13 (suppl 1):1-68.
6. Willey JZ, Rodriguez CJ, Carlino RF, et al. Race-ethnic differences in the association between lipid profile components and risk of myocardial infarction: The Northern Manhattan Study. Am Heart J. 2011;161(5):886-892.
7. Handelsman Y, Mechanick JI, Blonde L, et al; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(suppl 2):1-53.
8. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46(4):701-710.
9. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2011.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
11. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.
12. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM randomised trial. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072-2077.
13. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105.
14. DeFronzo RA, Tripathy D, Schwenke DC, et al; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104-1115.
15. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51(9):2796-2803.
16. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55(2):517-522.
17. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010;16(4):617-628.
18. Jones MR, Mudaliar S, Hernandez-Triana E, et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Curr Med Res Opin. 2009;25(9):2239-2249.
19. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006. http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20 of%20diabetes_new.pdf. Accessed March 21, 2011.
20. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30-35.
21. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-946.
22. Ryden L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Disesases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88-136.
23. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289-297.
24. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108(3 suppl):3B-24B.